NCT03122132View on ClinicalTrials.gov

Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 Weeks

CompletedOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

February 20, 2017

Primary Completion Date

January 1, 2018

Study Completion Date

March 1, 2018

Conditions
Hepatitis C Infection
Interventions
DRUG

ombitasvir/paritaprevir/ritonavir 8 weeks

Spanish cohort with HCV treated in real practice with ombitasvir/paritaprevir/ ritonavir 8 weeks

DRUG

dasabuvir 8 weeks

Spanish cohort with HCV treated in real practice with dasabuvir 8 weeks

Trial Locations (1)

08003

Carrion, Jose Antonio, PhD, Barcelona

All Listed Sponsors
lead

Hepa C

OTHER

NCT03122132 - Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 Weeks | Biotech Hunter | Biotech Hunter